Am Fam Physician. 2007 Jun 1;75(11):1653-1654.
Adenosine vs. Calcium Channel Blockers for Supraventricular Tachycardia
How do the safety and effectiveness of adenosine (Adenocard) and calcium channel blockers compare in the treatment of supra-ventricular tachycardia?
Adenosine and verapamil (Calan, Isoptin SR) are equally effective for treating acute supra-ventricular tachycardia in adults. Patients treated with adenosine have a higher rate of minor, transient adverse effects than patients treated with verapamil; however, rare but serious adverse effects may be more common with verapamil, especially in children. Although both agents are appropriate options, adenosine is generally the preferred initial agent.
Paroxysmal supraventricular tachycardia is usually caused by the development of a reentry circuit from anterograde and retrograde conduction through the atrioventricular node. In hemodynamically stable patients, initial management is focused on interrupting or modifying conduction in the atrioventricular node with vagal techniques (e.g., Valsalva maneuver, carotid artery massage, facial immersion in cold water). These techniques will terminate approximately 20 to 25 percent of episodes.1 If paroxysmal supra-ventricular tachycardia persists, adenosine and the nondihydropyridine calcium channel blockers verapamil and diltiazem (Cardizem) have been widely used for the condition.
This Cochrane review, which included eight studies and 577 total patients, found that adenosine and calcium channel blockers are equally effective in patients with paroxysmal supraventricular tachycardia. Only one study included children. Treatment groups in all studies were balanced in age and physiologic characteristics. However, most studies did not provide sufficient information about allocation concealment, blinding, and intention-to-treat analysis.
Minor adverse effects were more common in patients receiving adenosine, although the effects were typically short-lived. Conversely, major adverse effects, although uncommon, occurred only in patients treated with verapamil. These effects included two cardiac arrests (both occurred in children) and three episodes of hypotension.
Because of adenosine's rapid onset, short half-life, and favorable safety profile, the American College of Cardiology, American Heart Association (AHA), and European Society of Cardiology recommend adenosine as the preferred agent for the pharmacologic management of paroxysmal supraventricular tachycardia.2 The AHA Advanced Cardiac Life Support guideline recommends initially administering a 6-mg adenosine bolus over one to three seconds followed by a 20-mL saline flush.1 If this does not convert the rhythm, a 12-mg bolus should follow; a second 12-mg bolus may be given if the first is ineffective.1 Before adenosine is administered, patients should be counseled about the common adverse effects associated with the drug.
Nondihydropyridine calcium channel blockers should be second-line agents or used in patients with contraindications to adenosine. If the patient initially improves with adenosine therapy, but paroxysmal supraventricular tachycardia quickly returns, verapamil and diltiazem may be useful because of their longer half-lives. Ultimately, good clinical judgment based on the patient's characteristics, comorbidities, and preferences should guide the choice of agents.
Author disclosure: Nothing to disclose.
Holdgate A, Foo A. Adenosine versus intravenous calcium channel antagonists for the treatment of supraventricular tachycardia in adults. Cochrane Database Syst Rev. 2006;(4):CD005154.
1. 2005 American Heart Association guidelines for cardio-pulmonary resuscitation and emergency cardiovascular care. Part 7.3. Management of symptomatic bradycardia and tachycardia. Circulation. 2005;112;(suppl I): IV67–IV77.
2. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, et al. American College of Cardiology. American Heart Association. European Society of Cardiology. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. J Am Coll Cardiol. 2003;42:1493–531.
Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 1, 2021
Access the latest issue of American Family Physician